Jazz's Modeyso becomes first FDA-approved drug for type of aggressive brain cancer
6th August 2025 Uncategorised 0The FDA approved Jazz’s Modeyso (dordaviprone), which was picked up in the company’s $935 million buyout of Chimerix earlier this year, as the first systemic therapy for a rare type of brain cancer.
More: Jazz's Modeyso becomes first FDA-approved drug for type of aggressive brain cancer
Source: fierce